Skip to main content
News

COPD Drug Adherence Rates Among Patients on Various Combo Therapies


October 01, 2020

Patients with chronic obstructive pulmonary disease (COPD) who initiated combination treatment with umeclidinium/vilanterol had better medication adherence and were less likely to need rescue medication compared with patients who started with budesonide/formoterol, according to a study published in the International Journal of Chronic Obstructive Pulmonary Disease. 

“Based on this, our results suggest that patients treated with umeclidinium/vilanterol might have better control of their COPD symptoms than patients treated with budesonide/formoterol,” wrote researchers from GlaxoSmithKline.

The retrospective observational study included patients diagnosed with COPD, but not asthma and without any recent COPD flare-ups, who were starting maintenance therapy. Researchers evaluated data from a commercial insurance and Medicare Advantage database for 4082 patients taking umeclidinium/vilanterol and 9529 patients taking budesonide/formoterol. 

According to the study, patients taking umeclidinium/vilanterol had a significantly greater average proportion of days covered and significantly higher rates of medication adherence compared with patients taking budesonide/formoterol.

Additionally, a significantly smaller proportion of patients taking umeclidinium/vilanterol filled any rescue medications the year after initiating treatment, the study found. When they did require rescue medication, patients taking umeclidinium/vilanterol filled an estimated 17% fewer rescue medication canister equivalents than patients initiating budesonide/formoterol. 

“We calculated that the −0.37-unit difference in rescue medication use [between patient groups] in this study corresponds to a reduction of approximately 3 months’ supply over the entire follow-up period,” researchers wrote. 

Jolynn Tumolo 

Reference:

Moretz C, Cole AL, Mu G, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy. Int J Chron Obstruct Pulmon Dis. 2020;15:2207-2215. Published 2020 Sep 16. doi:10.2147/COPD.S259850

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
9 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top